Inovio Pharmaceuticals is trading 5% up at $1.24, with no clear company-specific catalyst identified.
- The latest notable announcement was the August 12 second-quarter update.
- It highlighted INO-3107’s advancing FDA review and October 30, 2026 PDUFA date, predating the current move.
- Broader markets are mixed and do not clearly explain the gain.